Hemophilia B | Executive Insights | US | 2023
Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in non-inhibitor patients) and bypass agents (in inhibitor patients). The main goal of factor IX prophylaxis and bypass agent treatment is to improve patients’ quality of life by reducing the frequency and severity of bleeding episodes. The hemophilia B therapy market is expected to transform over the next 10 years owing to the entry of several nonfactor and gene therapies. Supported by insights garnered from thought-leader interviews conducted by Clarivate, we analyze the current and future treatment of hemophilia B and the competitive landscape and identify key unmet needs and market drivers and challenges.
Questions answered
- What is the prevalence of hemophilia B in the United States? What are the key patient segments?
- What is the treatment algorithm for hemophilia B (+/- inhibitors)?
- Which drugs / drug classes are currently used in the management of hemophilia B? What are their key advantages and disadvantages?
- How will the use of standard half-life (SHL) and extended half-life (EHL) factor IX concentrate evolve with the launch of nonfactor therapies?
- What clinical roles will the emerging therapies fitusiran, concizumab, marstacimab, and gene therapy play in the treatment of hemophilia B?
- Which companies are currently offering or developing drugs to treat hemophilia B? What is their current and future market influence?
- What are the key unmet needs in hemophilia B treatment? How can they be addressed by pipeline drug therapies?
- What are the opinions of KOLs on different aspects of hemophilia B?
Product description
Executive Insights provides indication-specific market intelligence with world-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography: United States
Primary research: Three KOL interviews from February 2023
Key companies covered: Centessa Pharmaceuticals, CSL Behring, Freeline Therapeutics, Grifols, HEMA Biologics, Medexus Pharmaceuticals, Novo Nordisk, Pfizer, Sanofi, Takeda
Key drugs covered: AlphaNine, Alprolix, BeneFIX, concizumab, FEIBA, fidanacogene elaparvovec, fitusiran, Hemgenix, Idelvion, IXinity, marstacimab, NovoSeven, Profilnine, Rebinyn, Rixubis, SerpinPC, Sevenfact, verbrinacogene setparvovec
